Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunog...
Q1 2026
May 14, 2026
FY 2025
Mar 23, 2026
Q4 2025
Q3 2025
Nov 3, 2025
Q2 2025
Aug 14, 2025
